Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Medtronic plc    MDT   IE00BTN1Y115

MEDTRONIC PLC

(MDT)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
10/26/2020 10/27/2020 10/28/2020 10/29/2020 10/30/2020 Date
107.93(c) 105.21(c) 102.59(c) 101.37(c) 100.57(c) Last
5 763 760 5 023 438 7 090 004 4 858 230 5 838 042 Volume
-3.13% -2.52% -2.49% -1.19% -0.79% Change
More quotes
Financials (USD)
Sales 2021 29 168 M - -
Net income 2021 3 958 M - -
Net Debt 2021 19 560 M - -
P/E ratio 2021 34,6x
Yield 2021 2,24%
Sales 2022 32 216 M - -
Net income 2022 6 026 M - -
Net Debt 2022 16 604 M - -
P/E ratio 2022 22,4x
Yield 2022 2,36%
Capitalization 136 B 136 B -
EV / Sales 2021 5,34x
EV / Sales 2022 4,75x
Nbr of Employees 90 000
Free-Float 99,9%
More Financials
Company
Medtronic plc is one of the world leaders in designing, manufacturing and marketing of medical equipment. Net sales break down by sector of activity as follows: - general and minimally invasive surgery (28.9%): surgical equipment, intra-operative monitoring systems, ventilation systems, etc.; - vascular diseases and cardiac surgery (18.4%): coronary stents, endoprostheses for aortal pathologies, distal protection... 
More about the company
Notations Surperformance© of Medtronic plc
Trading Rating : Investor Rating :
More Ratings
All news about MEDTRONIC PLC
10:44aMEDTRONIC : Expands ENT Portfolio with FDA Clearance of NIM Vital Next Generatio..
AQ
10/29MEDTRONIC : Receives Health Canada Licence for the First-of-Its-Kind Percept&tra..
AQ
10/29MEDTRONIC : Expands ENT Portfolio with FDA Clearance of NIM Vital™ Next Ge..
PR
10/27MEDTRONIC : Venous Stent Receives U.S. FDA Approval to Treat Venous Outflow Obst..
AQ
10/26MEDTRONIC : 2020 CEO Letter to Shareholders
PU
10/26MEDTRONIC : Venous Stent Receives U.S. FDA Approval to Treat Venous Outflow Obst..
PR
10/21MEDTRONIC : Patients Report Superior, Sustained and Profound Back Pain Relief at..
AQ
10/19MEDTRONIC : Nine-Month Results from Medtronic IN.PACT BTK Study Presented in Lat..
AQ
10/18MEDTRONIC : Nine-Month Results from Medtronic IN.PACT BTK Study Presented in Lat..
PR
10/18MEDTRONIC : Nine-Month Results from Medtronic IN.PACT BTK Study Presented in Lat..
AQ
10/15MEDTRONIC : Biennial 2020 Investor & Analyst Meeting - Citations
PU
10/15MEDTRONIC : Named One of America's Most JUST Companies by Forbes and JUST Capita..
AQ
10/15MEDTRONIC : Launches Head-to-Head TAVR Study Comparing the Evolut TAVR Platform ..
AQ
10/15MEDTRONIC : Announces Partnership with The Foundry to Develop Innovative Mitral ..
AQ
10/15MEDTRONIC : Outlines Growth Strategy at Biennial Investor Day
AQ
More news
News in other languages on MEDTRONIC PLC
10/21Des entreprises américaines éligibles au PEA
10/01TOUR DU MONDE DES INDICES : l’Aristocratie souffre sur le S&P500, la Santé sauve..
10/01Le Capitole, c'est capital
10/01EN DIRECT DES MARCHES : Suez, Total, Worldline/Ingenico, STMicroelectronics, Gen..
08/25Le S&P-500 et le Nasdaq à des niveaux record, le Dow Jones en baisse
More news
Stock Trading Strategies
MEDTRONIC PLC - 07/16
Buying pressure
BUY
More Stock Trading Analysis
Chart MEDTRONIC PLC
Duration : Period :
Medtronic plc Technical Analysis Chart | MDT | IE00BTN1Y115 | MarketScreener
Technical analysis trends MEDTRONIC PLC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 27
Average target price 119,36 $
Last Close Price 100,57 $
Spread / Highest target 37,2%
Spread / Average Target 18,7%
Spread / Lowest Target -0,57%
EPS Revisions
Managers
NameTitle
Geoffrey Straub Martha Chief Executive Officer & Director
Omar S. Ishrak Executive Chairman
Mark Ploof Senior VP-Global Operations & Business Services
Karen L. Parkhill Chief Financial Officer & Executive Vice President
Richard E. Kuntz Senior VP, Chief Scientific & Clinical Officer
Sector and Competitors
1st jan.Capitalization (M$)
MEDTRONIC PLC-11.35%136 283
ABBOTT LABORATORIES20.88%185 906
BECTON, DICKINSON AND COMPANY-14.52%67 386
HOYA CORPORATION12.92%45 242
BAXTER INTERNATIONAL INC.-6.63%39 527
SARTORIUS STEDIM BIOTECH120.72%35 041